Target Protein Expression Profiling for TPD Development
* Please be kindly noted that our services and products can only be used for research to organizations or companies and not intended for any clinical or individuals.
Every targeted protein degradation (TPD) program starts with a deceptively simple question: is the target protein actually there, and is it there in the right place, at the right abundance, and in a form a degrader can reach? Target protein expression profiling answers that question. By quantifying a protein of interest across tissues, cell types, disease states, and subcellular compartments, and by mapping how it is expressed alongside the E3 ligase machinery a degrader must recruit, expression profiling converts a promising biology hypothesis into a testable degradation strategy. Whether the program uses PROTACs, molecular glues, LYTACs, AUTOTACs, AbTACs, or KineTACs, the design logic depends on the same evidence base: where the target lives, when it is expressed, how much is present, which form dominates, and which degradation machinery is available in the same cell.
BOC Sciences provides integrated target protein expression profiling services built specifically for TPD development. Our target protein services combine antibody-based quantification, endogenous reporter tagging, quantitative mass spectrometry, high-content imaging, and flow cytometry into a single profiling framework, then pair that data with custom protein expression and purification capabilities when a program needs matched protein reagents, cell models, or controls. The result is a complete expression context for your target that guides E3 ligase selection, cell model choice, dosing logic, and degrader design decisions before costly compound screening begins.
Request a Consultation Explore ServicesServices
BOC Sciences Target Protein Expression Profiling Services for TPD Development
Expression profiling for TPD is not a single experiment; it is a set of complementary measurements that describe a target from five angles: spatial, temporal, quantitative, qualitative, and E3-matched. The six service areas below show how BOC Sciences organizes these measurements, the representative experiments behind each one, and what each contributes to a degrader program.
Tissue and Cellular Target Protein Expression Profiling
We map where your target is expressed across disease and normal tissues and across individual cell populations, so a degrader program can be built around a measurable expression window rather than a single convenient model.
- Immunohistochemistry on tissue microarrays with H-score quantification
- Multiplex immunofluorescence for subcellular localization and tissue heterogeneity
- Flow cytometry and single-cell RNA sequencing for cell-subset resolution
Dynamic and Inducible Target Protein Expression Profiling
Many targets are not expressed at a constant level, so we capture how expression shifts over time, across the cell cycle, and in response to stimuli or pathway modulation, which defines the window in which a degrader has to act.
- Time-course Western blot and qPCR after serum, growth factor, or drug challenge
- Cell-cycle synchronization to identify phase-dependent expression peaks
- Hypoxia or DNA-damage induction to test stress-responsive expression
Subcellular and Post-Translational Modification Profiling
A degrader can only reach the protein that sits in an accessible compartment in a form the machinery can engage, so we resolve where the target resides and whether its activation, ubiquitination, and stability state favor degradation, and we connect the findings with binding affinity measurement when ligand context matters.
- Subcellular fractionation with compartment-specific Western blot
- Phospho-specific versus pan-protein Western blot for activation state
- Endogenous ubiquitination immunoprecipitation and cycloheximide-chase half-life mapping
Target Protein Isoform and Mutant Expression Profiling
Selective degradation of a disease-driving variant depends on knowing which form is actually present, so we determine whether an isoform, splice variant, fusion, or mutant dominates and at what proportion, so design can target the pathological form over its physiological relatives.
- Isoform- and mutant-specific antibody Western blot to resolve expression ratios
- PCR with Sanger sequencing to detect fusion transcripts and breakpoints
- Isogenic cell line comparison and top-down mass spectrometry for variant-level confirmation
Secreted and Circulating Target Protein Expression Profiling
Soluble and circulating forms of a target can escape intracellular degradation while still reflecting disease activity, so we quantify these pools to clarify whether an extracellular form matters and to support circulating biomarker readouts.
- Serum and plasma ELISA for circulating target levels
- Exosome isolation with Western blot to assess extracellularly carried target
- Multiplex cytokine and soluble factor profiling for pathway-level context
Target Protein and E3 Ligase Co-Expression Profiling
This is the measurement that sets TPD apart from conventional discovery: we determine whether the target and a candidate E3 ligase are co-expressed in the same cell, tissue, and compartment, and we confirm the ligase is functional through an E3 ubiquitin ligase activity assay.
- Dual immunohistochemistry and immunofluorescence for spatial co-localization
- Combined RNA sequencing for transcriptional co-expression correlation
- Quantitative proteomics with target-to-E3 stoichiometry to estimate degradation capacity
Need to Know Where and How Abundantly Your Target Is Expressed?
From tissue-level distribution to single-cell resolution, we map your target across models so your degrader program starts on solid ground.
Modalities
Target Protein Expression Profiling for Different TPD Modalities
Different degradation modalities interrogate different parts of a protein's expression context, so profiling has to follow the modality rather than a fixed checklist. The six programs below show how BOC Sciences tailors expression measurements to each degradation strategy.
PROTAC Target and E3 Ligase Expression Profiling
PROTACs act inside the cell, so profiling focuses on total intracellular target abundance and the co-expression of a recruitable ligase such as CRBN, VHL, IAP, or MDM2. The data feed directly into a PROTAC design for target proteins by confirming the chosen ligase is expressed and functional in the disease-relevant cells.
- Total intracellular target quantification across disease and normal models
- Nuclear and cytoplasmic pool separation to judge accessibility for larger molecules
- Confirmation of CRBN or VHL expression and activity in the intended cell context
Molecular Glue Target and E3 Substrate Receptor Expression Profiling
Molecular glues reinforce interactions that already exist, so the decisive measurements are whether the disease cell expresses the substrate and the required E3 substrate receptor, and whether a natural interface is available to stabilize. Our molecular glue technology development profiling pairs single-cell expression data with endogenous interaction mapping.
- Single-cell and spatial expression to confirm a disease-restricted expression window
- Endogenous interaction mapping to detect the natural weak interaction a glue can enhance
- Absolute proteomics to quantify substrate receptor levels
LYTAC Cell Surface Target and Lysosomal Receptor Expression Profiling
LYTAC degraders engage cell surface targets and route them to the lysosome through receptors such as the cation-independent mannose-6-phosphate receptor. Profiling therefore centers on the surface pool, an evaluation we integrate with LYTAC degradation technology development to confirm it is both abundant and reachable.
- Non-permeabilized surface quantification by flow cytometry
- Internalization kinetics measured by a surface biotinylation time course
- Lysosomal receptor and trafficking pathway expression and function
AUTOTAC Target Protein and p62/SQSTM1 Expression Profiling
AUTOTAC degraders exploit autophagy to clear aggregated or misfolded proteins, so the relevant profile combines aggregate burden, autophagic flux, and the expression and localization of the cargo receptor p62/SQSTM1, part of a broader AUTOTAC degradation technology development evaluation strategy.
- Aggregation tendency assessed by filter-trap and semi-denaturing assays
- Autophagic flux monitoring with LC3 reporters
- p62/SQSTM1 expression, localization, and organelle context
AbTAC Target and Transmembrane E3 Ligase Expression Profiling
AbTAC degraders are bifunctional antibodies that recruit transmembrane E3 ligases such as RNF43 to surface targets. Profiling covers epitope accessibility, membrane topology, and transmembrane ligase expression, work we align with AbTAC degradation technology development so that the target epitope and the ligase are confirmed to coexist on the same membrane.
- Epitope mapping and antibody clone screening for native-conformation accessibility
- Membrane topology analysis by protease protection and glycosylation profiling
- Transmembrane E3 ligase expression and membrane microdomain co-localization
KineTAC Target and Cytokine Receptor Expression Profiling
KineTAC degraders use cytokine receptors to carry surface targets into the lysosome. Expression profiling therefore pairs target surface density with the abundance of the relevant cytokine receptor and the cell's internalization capacity, measures we connect to our KineTAC technology development programs to predict whether a given cell model can support productive degradation.
- Target surface density and internalization capacity of the model
- Cytokine receptor expression and trafficking behavior
- Co-localization with endosomal and lysosomal markers
Need Help with Target Protein Expression Profiling?
Whether you face challenges in target expression analysis or need a tailored profiling strategy for your TPD project, BOC Sciences can provide solutions to support your research needs.
Value
Why Target Protein Expression Profiling Is Critical for TPD Success?
Define Degradation Window and Therapeutic Feasibility
A degrader can only remove the protein that is present. Expression data establish the baseline abundance that a degradation ability assay will later measure against, provide the reference point for DC50 and Dmax values, and reveal whether a favorable window exists between target expression in disease and normal cells.
Avoid Cell-Line Artifacts That Mask True Activity
A degrader that appears inactive may simply have been tested in cells that express little target or lack the recruited ligase. Profiling distinguishes pharmacological failure from model mismatch, so screening results reflect the compound rather than the assay system.
Inform E3 Ligase Selection and Tissue Targeting Strategy
Because ligase expression varies by tissue and cell type, profiling determines whether a CRBN-based or VHL-based recruiter is appropriate for a given target, and whether tissue-restricted ligases could improve selectivity.
Enable Reliable Activity-to-Toxicity Interpretation
Expression context is what allows degradation and selectivity evaluation to be read together, helping teams decide whether cellular effects follow from intended target loss or from unintended degradation in off-target tissues.
Applications
Applications of Target Protein Expression Profiling in TPD Development
Early Target Validation and Triage
Before committing chemistry resources, expression profiling determines whether a candidate target is present at a level and in a compartment that a degrader can address, allowing weak targets to be deprioritized and strong ones to move forward with evidence.
Cell Line Panel Optimization for PROTAC Screening
Selecting models for PROTAC high-throughput screening depends on knowing which lines express both the target and the recruited ligase. Profiling builds a fit-for-purpose panel so that screening capacity is spent on models that can actually report degradation.
E3 Ligase Strategy Selection
By mapping target and ligase expression together, profiling guides whether to pursue a conventional recruiter or an alternative ligase, and feeds directly into ligand design for target protein and warhead optimization decisions.
Disease-Relevant Model Characterization
Expression patterns differ across oncology, immune, neurological, and inflammatory models. Characterizing the intended disease model confirms that the biology a program depends on is genuinely present, and supports translation through PROTAC in vivo PD evaluation of degradation depth in tissue.
Workflow
Our Target Protein Expression Profiling Workflow
01
Project Consultation and Profiling Strategy Design
We review the target biology, intended TPD modality, E3 ligase hypothesis, disease area, and any existing expression or degradation data to define the profiling questions that matter most for your program.
02
Cell and Tissue Model Selection
We select cell lines, primary cells, and tissue samples that represent disease and normal contexts, prioritizing models in which both target and candidate E3 ligase can be evaluated within the same system.
03
Sample Preparation and Assay Optimization
Lysis, fractionation, fixation, and detection conditions are optimized for each target, including antibody validation and, where needed, protein ubiquitination readouts to link expression state with degradation potential.
04
Baseline and Spatial Protein Expression Profiling
We quantify baseline abundance and spatial distribution using tissue profiling, flow cytometry, imaging, and quantitative mass spectrometry to establish the expression reference that later degradation measurements are compared against.
05
Dynamic and Modality-Specific Expression Analysis
Depending on the degrader type, we add time-course, cell-cycle, stimulus-response, surface-internalization, aggregate-burden, or co-expression measurements, and connect them to mechanistic work such as a PROTAC ternary complex assay where productivity needs confirmation.
06
Data Integration and TPD Development Recommendations
Results are consolidated into a structured report that summarizes the target's expression context, highlights model and ligase options, and translates the findings into practical recommendations for degrader design and next-step experiments.
Turn Expression Data into a Degrader Design Blueprint
Connect target biology, E3 ligase availability, and model selection before your program commits to synthesis.
Why Us
Why Choose BOC Sciences for Target Protein Expression Profiling?
Multi-Platform Orthogonal Validation
No single method describes a target completely. We combine antibody-based detection, endogenous tagging, quantitative mass spectrometry, imaging, and flow cytometry so that abundance, location, and form are confirmed through independent approaches rather than a single readout.
Custom Cell Engineering Capability
When a target is low-abundance or lacks reliable antibodies, we can engineer reporter-tagged cell models and matched controls, generating the measurement tools a program needs when off-the-shelf reagents fall short.
Integrated Biology-to-Design Insight
Our scientists connect expression findings to degrader structure and mechanism, translating data from a PROTAC in vitro evaluation into concrete guidance on warhead, linker, and E3 ligand choices.
End-to-End TPD Service Ecosystem
Expression profiling links naturally to PROTAC design services, ligand discovery, degradation testing, and mechanism-focused assays, so a single partner can carry a program from target characterization to optimized degrader.
Case Study
Case Studies in Target Protein Expression Profiling for TPD Development
Project Background
A Japanese biotechnology company was developing a CRBN-recruiting degrader against a bromodomain-containing transcriptional regulator in a hematological malignancy. The compound worked in some cell lines but not others, with no clear link to target abundance, so the client needed to know whether the variability came from the target or from the degradation machinery.
Technical Challenges
The original dataset covered only a few lines and omitted CRBN expression, so responders could not be separated from non-responders. Warhead-linker analogs blurred compound versus cell-model effects, and the target had been measured with an antibody of uncertain specificity.
BOC Sciences Solutions
- Co-Expression Profiling Across an Expanded Panel: We profiled target abundance, CRBN transcript, and CRBN protein across 24 hematological and solid-tumor lines, using a validated antibody set and quantitative mass spectrometry to remove the specificity concern.
- Orthogonal Target Quantification: Western blot, capillary immunoassay, and targeted proteomics established a reproducible baseline for each model.
- Degradation-to-Expression Correlation: A PROTAC activity assay across the panel correlated degradation depth with target and CRBN levels to identify the true predictor of response.
Project Outcomes
Degradation tracked with CRBN expression rather than target abundance: "resistant" lines simply expressed too little CRBN. Among the 24 models, four combined high target and high CRBN co-expression and had not been used before; three responded with more than 80% target reduction. The client adopted two as primary screening models and retired the misleading "resistant" lines.
Project Background
A US pharmaceutical research team was evaluating a VHL-recruiting degrader against a nuclear hormone receptor restricted to a few tissues. Because the target is also expressed in normal hormone-responsive tissue, the team needed the expression window between normal and diseased cells and confirmation that the ligase was present in the same tissues.
Technical Challenges
The target belongs to a family of closely related members, so cross-reactivity was a real risk and earlier panels gave conflicting results. Spatial information was also needed to judge whether normal-tissue expression would create an unacceptable degradation footprint.
BOC Sciences Solutions
- Specificity-Controlled Tissue Profiling: Antibody specificity was confirmed with knockout and wild-type control lysates, then the target was profiled across a normal tissue panel and matched disease models by immunohistochemistry, quantifying intensity, positive rate, and localization.
- Spatial Ligase Co-Expression Mapping: Dual immunofluorescence showed whether VHL was co-expressed with the target in the same cell populations and compartments.
- Orthogonal Confirmation and Selectivity Context: Quantitative mass spectrometry confirmed tissue-level abundance, and PROTAC off-target evaluation examined whether related family members would be affected at the same exposure.
Project Outcomes
Target expression was markedly higher in disease tissue than in most normal tissues, with the main normal signal confined to one hormone-responsive organ; VHL co-expression was strong in the disease model but only moderate there, giving a measurable window. The target and its closest family member were clearly distinguished, and the client used these data to prioritize tissue-selective delivery.
Frequently Asked Questions (FAQ)
How are protein expression profiling methods selected for TPD research?
The selection of protein expression profiling methods depends on target biology, sample type, and the degradation mechanism being investigated. Western blotting and quantitative proteomics are useful for measuring protein abundance, while immunohistochemistry and immunofluorescence reveal tissue distribution and subcellular expression patterns. Flow cytometry is particularly valuable for analyzing cell surface proteins and expression differences among cell populations. For targets with multiple isoforms, mutations, or post-translational modifications, additional antibody-based or mass spectrometry approaches may be required. Combining complementary analytical methods helps researchers reduce assay-specific bias, establish reliable expression profiles, and select appropriate experimental models for subsequent targeted protein degradation studies.
Why is target and E3 ligase co-expression important for PROTAC development?
PROTAC-mediated degradation requires the target protein and a compatible E3 ubiquitin ligase to be available in a cellular environment that supports productive recruitment and ubiquitination. Measuring target abundance alone is therefore insufficient to evaluate degradation feasibility. Researchers can use western blotting or quantitative proteomics to compare target and E3 ligase expression, including CRBN and VHL, while immunofluorescence helps assess their subcellular distributions. These data support cell model selection, E3 ligase strategy development, and interpretation of differences in degradation activity across biological systems. However, co-expression does not guarantee productive ternary complex formation or efficient degradation, so functional confirmation remains necessary.
Why should protein turnover and dynamic expression be evaluated?
Target protein abundance can change in response to cell cycle progression, pathway activation, environmental conditions, and the balance between protein synthesis and degradation. Dynamic expression profiling helps researchers determine whether a target remains stable, increases after stimulation, or recovers following degrader treatment. Time-course western blotting, protein synthesis inhibition experiments, and combined mRNA and protein analysis can provide complementary information about protein turnover and compensatory expression. Understanding these changes helps define appropriate sampling points, interpret degradation depth and persistence, and distinguish direct protein depletion from secondary expression changes. Such information is particularly useful when comparing degrader candidates in disease-relevant cellular models.
How do expression profiling requirements differ across TPD modalities?
Expression profiling requirements vary according to the cellular machinery used by each degradation strategy. PROTACs and certain molecular glue degraders require attention to intracellular target abundance, relevant E3 ligase or substrate receptor expression, and subcellular distribution. LYTAC development places greater emphasis on cell surface target expression and lysosome-targeting receptor availability. AbTAC and KineTAC approaches additionally require characterization of compatible transmembrane E3 ligases or cytokine receptors, respectively. AUTOTAC research may involve evaluating target aggregation states and p62/SQSTM1 expression. These modality-specific expression data help researchers select experimental models and plan subsequent internalization, autophagy, degradation, or mechanism-validation assays appropriate to each strategy.
Can BOC Sciences profile low-abundance or challenging target proteins?
Yes. Low-abundance proteins, membrane-associated targets, and proteins with multiple isoforms can present significant challenges for conventional expression analysis. BOC Sciences develops tailored profiling strategies based on target characteristics and sample availability. Our approach may combine optimized protein extraction, sample enrichment, western blotting, immunofluorescence, flow cytometry, and targeted proteomics. For low-abundance targets, we evaluate enrichment strategies and sensitive detection methods. Membrane proteins may require membrane fractionation or cell surface staining, while isoform-specific analysis can involve selective antibodies and mass spectrometry. By integrating complementary analytical approaches and appropriate experimental controls, we help researchers obtain more reliable expression data and establish a stronger foundation for subsequent targeted protein degradation studies.
Testimonials
Client Testimonials on Target Protein Expression Profiling
Comprehensive and Reliable Protein Expression Data
"We had conflicting expression results from internal studies and needed a definitive answer. The profiling combined several detection methods, and the agreement between them gave us confidence in the baseline we used for all of our subsequent degradation work."
— Dr. Ward, Head of Target Biology at a European Biotech Firm
Valuable Insights into Target and E3 Ligase Co-Expression
"What made the biggest difference was seeing target and ligase expression side by side. It explained variability we had been struggling with for months and told us directly which models could support our degrader."
— Ms. Mendoza, Senior Scientist at a Nordic Pharmaceutical Research Group
Effective Support for TPD Model Selection
"We saved significant time by selecting our screening models based on expression profiling rather than trial and error. The recommended cell lines behaved exactly as predicted, which let us move into optimization far faster."
— Dr. Castillo, Project Manager at a US Oncology-Focused Biotech
Customized Profiling Solutions and Expert Guidance
"Our target had no reliable antibody and low endogenous abundance, which had blocked us before. The team designed a custom profiling approach and explained the reasoning at every step, turning a difficult target into a workable one."
— Dr. Reed, Discovery Biology Lead at a UK-Based Research Organization
* PROTAC® is a registered trademark of Arvinas Operations, Inc., and is used under license.
BOC Sciences Support
Please contact us with any specific requirements and we will get back to you as soon as possible.
